Literature DB >> 14066149

DEPRESSION OF THE VASOMOTOR CENTRE BY MECAMYLAMINE, INDEPENDENT OF ITS GANGLION-BLOCKING ACTIVITY.

K P BHARGAVA, K N DHAWAN.   

Abstract

Mecamylamine depressed the vasomotor centre independently of its ganglion-blocking action. The central action was elicited by small amounts of the drug when it was confined to the central nervous system of dogs and cats anaesthetized with pentobarbital sodium and of spinal cats. The spinal site of action was shown by the inhibition of vasomotor responses due to spinal compression in cats, when mecamylamine was introduced intrathecally in a dose too small to block autonomic ganglia. The supraspinal site of action was shown by intravertebral arterial injection of mecamylamine into cats, which caused hypotension and selectively blocked the electrically evoked pressor responses from the medulla without affecting the "nicotinic" ganglionic responses to acetylcholine. Injection of mecamylamine into the cerebral ventricles of dogs produced hypotension, and the reflex vasomotor responses to stimulation of afferent fibres in the vagus nerves and to occlusion of the common carotid arteries were inhibited without any change in the response of the nictitating membrane to preganglionic nervous stimulation.

Entities:  

Keywords:  CATS; EXPERIMENTAL LAB STUDY; MECAMYLAMINE; PHARMACOLOGY; VASOMOTOR SYSTEM

Mesh:

Substances:

Year:  1963        PMID: 14066149      PMCID: PMC1703867          DOI: 10.1111/j.1476-5381.1963.tb01499.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN: 0366-0826


  15 in total

1.  The spinal compression vasomotor response as a pharmacological tool.

Authors:  K P BHARGAVA; J K KULSRESHTHA
Journal:  Arch Int Pharmacodyn Ther       Date:  1959-05-01

2.  Do ganglion-blocking agents and reserpine affect central vasomotor activity?

Authors:  J W McCUBBIN; I H PAGE
Journal:  Circ Res       Date:  1958-11       Impact factor: 17.367

3.  Neurological manifestations after antihypertensive therapy with mecamylamine.

Authors:  H M PERRY; H A SCHROEDER
Journal:  J Am Med Assoc       Date:  1957-07-27

4.  Mecamylamine and its mode of action.

Authors:  G BENNETT; C TYLER; E ZAIMIS
Journal:  Lancet       Date:  1957-08-03       Impact factor: 79.321

5.  Hypotensive and ganglion blocking action of methyl substituted 3-amino-norcamphanes.

Authors:  K RUBINSTEIN; J G PEDERSEN; J FAKSTORP; V RONNOV-JESSEN
Journal:  Experientia       Date:  1958-06-15

6.  The hypotensive action of mercamylamine.

Authors:  A E DOYLE; E A MURPHY; G H NEILSON
Journal:  Br Med J       Date:  1956-11-24

7.  Mecamylamine in treatment of hypertensive disease; observations on an unusual neuromuscular complication.

Authors:  A C CORCORAN; H P DUSTAN; I H PAGE; R E SCHNECKLOTH
Journal:  J Am Med Assoc       Date:  1956-10-27

8.  Use of mecamylamine in the management of hypertension.

Authors:  E G MCQUEEN; F H SMIRK
Journal:  Br Med J       Date:  1957-02-23

9.  Ganglionic blocking properties of 3-methylaminoisocamphane hydrochloride (mecamylamine): a secondary amine.

Authors:  C A STONE; M L TORCHIANA; A NAVARRO; K H BEYER
Journal:  J Pharmacol Exp Ther       Date:  1956-06       Impact factor: 4.030

10.  Pharmacological properties of pempidine (1:2:2:6:6-pentamethylpiperidine), a new ganglion-blocking compound.

Authors:  S J CORNE; N D EDGE
Journal:  Br J Pharmacol Chemother       Date:  1958-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.